Evidence map›Paper›PMID 41520055›Full record

ArticleInternational journal of obesity (2005)2026

Insulin resistance modulates gut microbiota and incretin response remodeling after bariatric surgery in severe obesity.

Rocío Puig, M-Mar Rodríguez-Peña, Laura Hernández-Montoliu, Brenno Astiarraga, Eva Martínez, Jose M Balibrea, Gemma Llauradó, Jordi Tarascó, Albert Caballero, Clara Joaquín and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rocío Puig *Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0001-9184-5583
M-Mar Rodríguez-Peña *Department of Endocrinology and Nutrition, Hospital Universitari Joan XXIII de Tarragona, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.ORCID 0000-0003-2553-9769
Laura Hernández-MontoliuDepartment of Endocrinology and Nutrition, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0003-3935-3922
Brenno AstiarragaDepartment of Endocrinology and Nutrition, Hospital Universitari Joan XXIII de Tarragona, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.ORCID 0000-0003-2216-8974
Eva MartínezClinical Nutrition Unit. Hospital Germans Trias i Pujol, Badalona, Spain.
Jose M BalibreaDepartment of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0002-0764-7179
Gemma LlauradóCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID 0000-0002-3237-6366
Jordi TarascóDepartment of General and Gastrointestinal Surgery. Health Sciences Research Institute and University Hospital Germans Trias i Pujol, Badalona, Spain.ORCID 0000-0001-6820-7946
Albert CaballeroDepartment of General and Gastrointestinal Surgery. Health Sciences Research Institute and University Hospital Germans Trias i Pujol, Badalona, Spain.ORCID 0000-0003-2666-4967
Clara JoaquínDepartment of Endocrinology and Nutrition. Health Sciences Research Institute and University Hospital Germans Trias i Pujol, Badalona, Spain.ORCID 0000-0002-9063-4853
Manel Puig-DomingoDepartment of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0002-6744-7195
Nuria VilarrasaCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID 0000-0003-3188-1990
Sonia Fernández-VeledoDepartment of Endocrinology and Nutrition, Hospital Universitari Joan XXIII de Tarragona, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.ORCID 0000-0003-2906-3788
Joan VendrellDepartment of Endocrinology and Nutrition, Hospital Universitari Joan XXIII de Tarragona, Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.ORCID 0000-0002-6994-6115
Silvia PelliteroDepartment of Endocrinology and Nutrition. Health Sciences Research Institute and University Hospital Germans Trias i Pujol, Badalona, Spain. spellitero.germanstrias@gencat.cat.ORCID 0000-0002-9510-7251

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to assess the impact of insulin resistance (IR) on gut microbiota (GM) composition, incretin responses, and metabolic outcomes following sleeve gastrectomy (SG) in people with severe obesity who do not have diabetes.

methodsA prospective single-center study encompassed patients with severe obesity and normal glucose tolerance who underwent SG. Participants were stratified into two cohorts based on the magnitude of their insulin resistance state, as determined by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index: high-IR (Hi-IR; HOMA-IR > 95th percentile) and low-IR (Lo-IR; HOMA-IR <25th percentile). Body composition measurements, biochemical analyses, and microbiota assessments were performed before and 6 months post-surgery. Additionally, the responses to a standardized meal tolerance test (MTT) of glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) were evaluated.

resultsThe study cohort consisted of 18 patients (9 with Hi-IR and 9 with Lo-IR), with a mean age of 48.8 ± 9.2 years and a mean body mass index (BMI) of 45.03 ± 4.82 kg/m². Six months post-surgery, the mean percentage of total weight loss (WL) was 26.5 ± 6%, with both groups exhibiting enhanced secretion of GLP-1 and GLP-2 following MTT. At baseline, participants exhibited distinct microbiota profiles; the Hi-IR group showed a higher relative abundance of Prevotella species, which are previously associated with adverse metabolic and inflammatory profiles. Post-surgery, both groups exhibited positive incretin responses and significant modifications in GM composition. Notably, Hi-IR people experienced more pronounced changes in microbial diversity, including increases in Akkermansia and Veillonella species and decreases in Prevotella species. Enhanced GLP-1 and GLP-2 responses were correlated with WL and metabolic improvement, particularly in the Lo-IR population.

conclusionsThese findings underscore the role of GM in metabolic changes and surgical outcomes after SG. Targeting gut microbiota may offer a promising avenue for improving obesity treatment strategies.

Indexed as

Bariatric SurgeryGastrointestinal MicrobiomeIncretinsInsulin ResistanceObesity, MorbidAdultFemaleGlucagon-Like Peptide 1HumansMaleMiddle AgedProspective StudiesGlucagon-Like Peptide 1Incretins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.